2019
Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation
Chandhok N, Huntington S, Isufi I, Gowda L, Xu M, Bar N, Seropian S, Foss F. Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation. Blood 2019, 134: 4055. DOI: 10.1182/blood-2019-128888.Peer-Reviewed Original ResearchAutologous stem cell transplantationAggressive T-cell lymphomaProgression-free survivalT-cell lymphomaTime of diagnosisPeripheral blood involvementBone marrow involvementStem cell transplantationMedian progression-free survivalOverall survivalCell lymphomaBlood involvementFirst remissionMarrow involvementPrognostic factorsCell transplantationFlow cytometryPeripheral bloodWorse outcomesPositive groupNegative groupExtranodal natural killer T-cell lymphomaBone marrowFront autologous stem cell transplantationNatural killer T-cell lymphoma
2016
Autologous Stem Cell Mobilization in the Age of Plerixafor
Cooper DL, Medoff E, Patel N, Baker J, Pratt K, Foss F, Seropian SE, Perreault S, Wu Y. Autologous Stem Cell Mobilization in the Age of Plerixafor. Clinical Lymphoma Myeloma & Leukemia 2016, 16: 411-416. PMID: 27245311, DOI: 10.1016/j.clml.2016.04.007.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntigens, CD34BenzylaminesCyclamsFemaleGraft SurvivalGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationHematopoietic Stem CellsHeterocyclic CompoundsHumansLymphomaMaleMiddle AgedMultiple MyelomaTreatment OutcomeWorkflowConceptsStem cell mobilizationCell mobilizationPlerixafor useG-CSFAutologous stem cell transplantationAutologous stem cell mobilizationGranulocyte-colony stimulating factor (G-CSF) mobilizationDose of plerixaforLess platelet transfusionsStem cell transplantationCD34 cells/Treatment of myelomaCells/High-risk factorsEnough stem cellsStem cellsHematologic tolerancePosttransplantation therapyRelapsed lymphomaPlatelet transfusionsCell transplantationRisk factorsFactor mobilizationPatientsPlerixafor